NEXTSTELLIS® oral contraceptive has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent

,

2 August 2022, 07:30 CEST, Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent. After France and Belgium, the contraceptive developed by Mithra is selected for the third time by the Galien Prize, the most prestigious award of the pharmaceutical research and innovation.